Accrued Expenses and Restructuring Reserve (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019		Dec. 31, 2018
Accrued Expenses and Other Liabilities [Abstract]
Accrued research and development costs	$ 132,538		$ 71,329
Accrued professional fees	230,337		421,617
Accrued compensation	489,863		54,269
Accrued other	0		46,674
Accrued rent termination	443,868		8,000
Total	1,296,606		601,889
Restructuring Reserve [Abstract]
Restructuring reserve	858,332	[1]	0
Total	858,332		$ 0
Restructuring expense paid	$ 1,211,939

[1] Restructuring reserve relates to the severance costs incurred by Edge Therapeutics prior to the merger transaction and assumed by the Company as part of the purchase accounting, but not yet paid. The severance costs continue through September 2020. For the nine months ended September 30, 2019, the Company paid $1,211,939 of restructuring expense which was previously recorded on Edge Therapeutics financials.